View Older Stories

Jan 12, 2026 04:02PM SciSparc receives NASDAQ notice for minimum equity non-compliance

Dec 30, 2025 08:18AM NeuroThera Labs receives Israeli patent for opioid combination technology

Dec 1, 2025 08:32AM SciSparc to acquire GERD device portfolio from Xylo Technologies

Nov 20, 2025 06:45AM SciSparc files Israeli patent for depression treatment combination therapy

Nov 17, 2025 07:55AM Clearmind Medicine files Israeli patent for depression treatment

Oct 30, 2025 09:25AM N2OFF completes merger with cancer drug discovery firm MitoCareX

Oct 24, 2025 07:55AM SciSparc acquires controlling stake in TSXV-listed Neurothera Labs

Oct 23, 2025 04:04PM SciSparc completes sale of MitoCareX subsidiary to N2OFF for $700,000

Oct 23, 2025 08:58AM SciSparc launches quantum computing initiative for drug discovery

Oct 23, 2025 08:26AM N2OFF completes acquisition of cancer drug discovery firm MitoCareX

Oct 20, 2025 07:42AM SciSparc and Clearmind publish patent application for binge disorders

Oct 15, 2025 07:05AM SciSparc to acquire TSXV company for $11.6 million asset transfer

Oct 6, 2025 06:41AM SciSparc terminates merger deal with AutoMax Motors

Sep 29, 2025 04:03PM N2OFF shareholders approve acquisition of MitoCareX drug discovery unit

Sep 25, 2025 04:01PM N2OFF stockholders approve MitoCareX acquisition

Sep 25, 2025 07:05AM SciSparc plans quantum computing initiative for drug discovery

Aug 28, 2025 09:24AM SciSparc shareholders approve merger with Israeli auto importer AutoMax

Aug 28, 2025 06:53AM SciSparc shareholders approve merger with vehicle importer AutoMax

Aug 7, 2025 07:32AM Clearmind Medicine receives patent publication for obesity therapy

Jul 30, 2025 04:36PM SciSparc merger registration statement declared effective by SEC

Jul 30, 2025 08:21AM Clearmind Medicine files patent for obesity and liver disease therapy

Jul 22, 2025 09:08AM SciSparc regains compliance with NASDAQ minimum bid price rule

Jun 24, 2025 05:03PM SciSparc (SPRC) Announces 1:21 Reverse Share Split

May 27, 2025 07:32AM SciSparc (SPRC) Announces Publication of Japanese Patent Application

Apr 25, 2025 08:00AM SciSparc (SPRC) -Clearmind (CMND) Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Mar 10, 2025 07:27AM Clearmind Medicine (CMND) Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

Mar 3, 2025 08:25AM SciSparc (SPRC) to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

Feb 27, 2025 08:45AM SciSparc (SPRC) Extends $2M Loan to Support AutoMax's Growth

Feb 26, 2025 09:29AM N2OFF (NITO) Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers

Feb 18, 2025 07:17AM SciSparc (SPRC) Secures Favorable Settlement in Lawsuit It Filed

Jan 15, 2025 07:34AM SciSparc (SPRC) Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Jan 13, 2025 08:41AM SciSparc (SPRC) Reports AutoMax Entered the Direct Import Market with a $13M First Shipment of JAC Electric Vehicles

Jan 6, 2025 08:15AM Clearmind Medicine (CMND) Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Jan 6, 2025 07:50AM SciSparc (SPRC) and Clearmind (CNMD) Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Dec 31, 2024 09:27AM SciSparc (SPRC) Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

Dec 26, 2024 06:47AM SciSparc (SPRC): AutoMax Announces $13M First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

Dec 16, 2024 07:43AM SciSparc (SPRC) Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

Sep 30, 2024 09:25AM SciSparc (SPRC) Secures FDA Green Light to US Launch of Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 26, 2024 09:06AM SciSparc (SPRC) Enters LoI to Sell Stake in MitoCareX

Sep 23, 2024 08:17AM SciSparc (SPRC) Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 18, 2024 04:09PM SciSparc (SPRC) Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 16, 2024 04:06PM Clearmind Medicine (CMND) Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy

Sep 11, 2024 07:40AM SciSparc (SPRC) Advances $1.85M Loan to AutoMax

Sep 6, 2024 07:56AM Clearmind Medicine (CMND) Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Aug 29, 2024 04:26PM Clearmind Medicine (CMND) Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment

Aug 28, 2024 08:55AM SciSparc (SPRC) Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

Aug 22, 2024 08:16AM SciSparc (SPRC): MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board

Aug 19, 2024 04:11PM SciSparc (SPRC) Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment

Aug 14, 2024 04:54PM SciSparc (SPRC) Issues Update Regarding the Status of the AutoMax Merger

Aug 6, 2024 08:58AM SciSparc (SPRC) and Clearmind Medicine (CNMD) Announce New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

View Older Stories